Skip to content

Study · Not a test of the peptide alone · 2000

2 results

[Immunocorrective effect of cycloferon and thymogen in patients with uterine cancer].

Antipova SV

Likars'ka sprava1 Oct 2000

PMID16786663 (opens in a new tab)PepBankPUB-16786663
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

  1. 01HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In women with uterine cancer, cycloferon and thymogen treatment normalized immune status measures.

    In plain wordsIn women with uterine cancer, treatment with cycloferon and thymogen was linked to normalized immune measures.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableImmune status normalization
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The employment of cyclopheronum and thymogenum makes for normalization of values for the immune status.
    1 context sentence
    Summary · context
    Those women diagnosed as having hysterocarcinoma demonstrate even before surgery pronounced immunological disturbances tending to progress after surgical intervention.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In women with uterine cancer, cycloferon and thymogen treatment was associated with a more favourable postoperative course.

    In plain wordsIn women with uterine cancer, cycloferon and thymogen treatment was linked to a better postoperative course.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Direction not reportedPostoperative course
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Cancer

    Source sentences

    Summary
    Clinically, this is accompanied by a more favourable postoperative course.
    2 context sentences
    Summary · context
    The employment of cyclopheronum and thymogenum makes for normalization of values for the immune status.
    Summary · context
    Those women diagnosed as having hysterocarcinoma demonstrate even before surgery pronounced immunological disturbances tending to progress after surgical intervention.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.